cardiovascular risk

Addressing Under-Detection of Sleep Apnea in Black Individuals: The Role of Racial Differences in Oxygen Desaturation and Heart-Rate Response

By MedXY 11/11/2026

This article examines how pulse oximetry may under-detect sleep apnea events in Black individuals due to skin pigmentation-related measurement bias, highlighting heart-rate response as a reliable, pigmentation-independent marker predictive of cardiovascular risk.

Cardiology Clinical Updates OB/GYN & Women's Health

Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy

By MedXY 11/08/2026

This review synthesizes evidence from randomized trials indicating that baseline lipid profiles significantly modify coronary heart disease risk associated with oral menopausal hormone therapy, underscoring the importance of lipid assessment for personalized therapy.

靶向心血管风险相关炎症：口服 NLRP3 抑制剂 Ruvonoflast 的疗效与安全性

Cardiology Clinical Updates Diabetes & Endocrinology

Targeting Inflammation in Cardiovascular Risk: Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast

By MedXY 11/08/2026

This Phase 1b trial demonstrates that oral NLRP3 inhibition with ruvonoflast markedly reduces systemic inflammatory biomarkers in obese individuals at elevated cardiovascular risk, with favorable safety and tolerability, supporting further clinical development.

Cardiology Clinical Updates OB/GYN & Women's Health

Decoding Anti-Müllerian Hormone Trajectories During Menopause: Implications for Cardiovascular Health

By MedXY 11/06/2026

Analysis of anti-müllerian hormone (AMH) trajectories reveals two distinct decline patterns across menopause, with slower AMH decline linked to higher postmenopausal cardiovascular risk, independent of premenopausal risk factors.

绝经后慢性肾脏病女性的心血管风险预测：来自 Women’s Health Initiative 的研究启示

Cardiology Clinical Updates Nephrology

Assessing Cardiovascular Risk Prediction Models in Postmenopausal Women With Chronic Kidney Disease: Insights from the Women’s Health Initiative

By MedXY 11/03/2026

Cardiovascular risk prediction models show limited accuracy in postmenopausal women with chronic kidney disease, often underestimating risk, highlighting the need for improved tools in this high-risk population.

Cardiology Clinical Updates

Modulating Coronary Artery Calcification Progression: Insights from the DANCODE Trial on Vitamin K2 and D3 Supplementation

By MedXY 11/03/2026

The DANCODE trial demonstrates that combined vitamin K2 and D3 supplementation reduces the progression of severe coronary artery calcification over 24 months without increasing noncalcified plaque burden, offering a promising adjunctive strategy in cardiovascular risk management.

Cardiology Clinical Updates Diabetes & Endocrinology

Metyrapone Treatment in Mild Autonomous Cortisol Secretion: Cardiovascular Benefits and Mechanistic Insights

By MedXY 11/02/2026

A 12-week metyrapone regimen lowers blood pressure and reduces epicardial fat in patients with mild autonomous cortisol secretion, suggesting cardiovascular improvements without altering cardiac morphology or function.

Cardiology Clinical Updates Pediatrics

Early Cholesterol-Lowering Therapy in Familial Hypercholesterolaemia: Insights from the SAFEHEART Study

By MedXY 11/01/2026

Initiating cholesterol-lowering therapy during childhood in familial hypercholesterolaemia substantially reduces LDL-C burden and cardiovascular risk, highlighting the importance of early diagnosis and treatment.

SMART-REACH2：用于预测终生心血管风险并优化已确诊动脉粥样硬化性心血管疾病预防治疗的全球模型

Cardiology Clinical Updates

SMART-REACH2: A Global Model for Predicting Lifetime Cardiovascular Risk and Tailoring Preventive Therapy in Established Atherosclerotic Disease

By MedXY 10/31/2026

The SMART-REACH2 model estimates lifetime recurrent cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease, offering region-specific recalibration and supporting personalized shared decision-making.

Clinical Updates Diabetes & Endocrinology OB/GYN & Women's Health

Reevaluating the Safety and Clinical Implications of Menopausal Hormone Therapy: A Contemporary Perspective

By MedXY 10/30/2026

Menopausal hormone therapy remains the most effective treatment for estrogen deficiency symptoms, with a favorable benefit-risk profile when individualized by age, timing, and formulation. Emerging evidence refines safety perceptions, guiding tailored clinical decisions.

Internal Medicine news Superintelligence

AI-Derived Panoramic Radiograph Score Links Oral Health to Major Systemic Diseases

By MedXY 10/24/2026

An AI-generated panoramic dental imaging score correlates independently with diabetes, hypertension, ischemic heart disease, osteoporosis, and hyperlipidemia, supporting integrated medical-dental care.

Cardiology Diabetes & Endocrinology news

Unraveling the Cardiovascular Benefits of Semaglutide: Insights from the SELECT Trial Mediation Analysis

By MedXY 09/28/2026

The SELECT trial demonstrates semaglutide's 20% reduction in major cardiovascular events in adults with obesity and cardiovascular disease. Mediation analysis reveals partial but uncertain roles of weight, inflammation, and glycemic markers, highlighting the need for further mechanistic research.

Cardiology Hematology-Oncology news

Genetically Mediated LDL Cholesterol Variations and Their Limited Impact on Venous Thromboembolism Risk

By MedXY 09/25/2026

This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.

Cardiology news

Enhancing Prognosis in Stable Coronary Artery Disease: Insights from a Nationwide Cohort on FFR-CT

By MedXY 09/25/2026

This large nationwide study demonstrates that coronary CTA-derived FFR-CT strongly predicts future myocardial infarction, cardiovascular death, and revascularization, independent of traditional risk factors and stenosis severity, with a threshold value of 0.67 defining increased risk.

Cardiology Diabetes & Endocrinology news

Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management

By MedXY 09/22/2026

This study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing's syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.

Cardiology Clinical Updates Nephrology news

Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review

By MedXY 09/20/2026

Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.

Cardiology Internal Medicine news

A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to Know

By MedXY 09/20/2026

Concise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for very-high-risk secondary prevention.

Cardiology Gastroenterology news

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective Study

By MedXY 09/15/2026

Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and inform prevention strategies.

Cardiology news

Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular Risk

By MedXY 09/15/2026

Nighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and sleep for heart health.

Cardiology news OB/GYN & Women's Health

Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study

By MedXY 09/13/2026

Initiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 years of menopause onset.